ReSTOR IOL good in post LASIK cataract patients

Article

The use of the ReSTOR intraocular lens (IOL) (Alcon) for patients requiring cataract surgery after prior laser photoablation can result in excellent outcomes if optical results fall near emmetropia, according to Samuel Masket of the USA.

The use of the ReSTOR intraocular lens (IOL) (Alcon) for patients requiring cataract surgery after prior laser photoablation can result in excellent outcomes if optical results fall near emmetropia, according to Samuel Masket of the USA.

A total of 16 eyes of 11 patients were chosen to receive the lens after discussing thoroughly the risks, benefits and alternative lens options. Presurgical biometry was performed by partial coherence interferometry and appropriate formulae applied for IOL power calculation.

Surgery was performed using topical and intracameral anaesthesia employing phacoemulsification through clear corneal temporal incisions. Five patients underwent bilateral surgery while the remaining six required surgery in just one eye.

The results showed that all five bilateral patients were fully independent of spectacles after surgery and that, in all, ten of the eleven patients were very satisfied with the visual outcomes. One patient was moderately dissatisfied despite achieving 20/25 and J2+ uncorrected visual acuities. There were no complications of surgery and no IOLs were removed or exchanged.

Masket concluded that the ReSTOR IOL offers a good option for patients needing cataract surgery after laser photoablation.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.